Suven Life Sciences Ltd has been granted two product patents in Canada and one product patent in Eurasia corresponding to the new chemical entities for the treatment of disorders associated with neurodegenerative diseases.
These three patents are valid up to 2028, the company informed the stock exchanges today.
Venkat Jasti, CEO of Suven Life, in a statement said: “The grant of these patents for our pipeline of molecules being developed for cognitive disorders is aimed at meeting the unmet medical needs. It has huge market potential globally.’’
The granted claims of the patents include the class of selective compounds discovered by Suven and are being developed as therapeutic agents.
These are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, attention deficient hyperactivity disorder, Huntington’s disease, Parkinson and Schizophrenia.
With the grant of these new patents, Suven has 12 granted patents from Canada and 13 product patents from Eurasia. These are exclusive intellectual property of Suven developed through internal discovery research efforts.
Products out of these inventions may be out-licensed at various phases of clinical development, it further said.